Dermatitis News

The National Eczema Association has dedicated October to raising awareness of this inflammatory skin condition, with 2022 focused on the facts of the disease as well as the stories of those who live with it.

Infants at high risk for atopic dermatitis who used emollients daily through their first 2 months of life experienced less disease in their first year than high-risk infants who did not use emollients, according to study results.

LEO Pharma has partnered with eczema patient advocate Ashley Ann Lora for the “AD Days Around the World” campaign, an effort to document the stories of individuals living with atopic dermatitis to help inspire others.

Remibrutinib appeared very effective in treating moderate to severe chronic spontaneous urticaria, with a rapid onset of action and a favorable safety profile, according to a study published in The Journal of Allergy & Clinical Immunology.

Patients with atopic dermatitis who are on Janus kinase inhibitors did not show an increased risk for venous thromboembolism, according to a study.

Researchers have long questioned whether the microscopic Demodex mite is a cause or effect of rosacea, a skin condition affecting 16 million Americans.

MILAN — In patients with seborrheic dermatitis, once-daily roflumilast foam had a significant impact on skin clearance and itch response and was tolerated well, according to phase 3 trial results.

The European Medicines Agency has recommended extending the use of Adtralza in the European Union to adolescents with moderate to severe atopic dermatitis, according to a LEO Pharma press release.

In patients with atopic dermatitis, ruxolitinib cream significantly reduced itch during two phase 3 trials.

MILAN — Roflumilast foam was well tolerated and efficacious in seborrheic dermatitis patients with all skin types, according to a poster presented at the European Academy of Dermatology and Venereology Congress.